BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 34737700)

  • 1. Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies.
    Singla RK; Sharma P; Dubey AK; Gundamaraju R; Kumar D; Kumar S; Madaan R; Shri R; Tsagkaris C; Parisi S; Joon S; Singla S; Kamal MA; Shen B
    Front Pharmacol; 2021; 12():732266. PubMed ID: 34737700
    [No Abstract]   [Full Text] [Related]  

  • 2. Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies.
    Singla RK; Sai CS; Chopra H; Behzad S; Bansal H; Goyal R; Gautam RK; Tsagkaris C; Joon S; Singla S; Shen B
    Front Cell Dev Biol; 2021; 9():745177. PubMed ID: 34805155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid hormone synthetic pathways in prostate cancer.
    Mostaghel EA
    Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor.
    Tilki D; Schaeffer EM; Evans CP
    Eur Urol Focus; 2016 Dec; 2(5):499-505. PubMed ID: 28723515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and prevalence of castration-resistant prostate cancer subtypes.
    Vellky JE; Ricke WA
    Neoplasia; 2020 Nov; 22(11):566-575. PubMed ID: 32980775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.
    Zhang W; Lee AM; Jena S; Huang Y; Ho Y; Tietz KT; Miller CR; Su MC; Mentzer J; Ling AL; Li Y; Dehm SM; Huang RS
    Proc Natl Acad Sci U S A; 2023 Apr; 120(17):e2218522120. PubMed ID: 37068243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
    Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
    Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
    Brown NE; Jones A; Hunt BG; Waltz SE
    Prostate; 2022 Nov; 82(15):1422-1437. PubMed ID: 35860905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary Tomato or Lycopene Do Not Reduce Castration-Resistant Prostate Cancer Progression in a Murine Model.
    Rowles JL; Smith JW; Applegate CC; Miller RJ; Wallig MA; Kaur A; Sarol JN; Musaad S; Clinton SK; O'Brien WD; Erdman JW
    J Nutr; 2020 Jul; 150(7):1808-1817. PubMed ID: 32369574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.